BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36787504)

  • 1. Clearance Profile of Circulating Tumor Human Papillomavirus DNA During Radiotherapy Predicts Clinical Outcomes in Human Papillomavirus-Related Oropharyngeal Cancer.
    Tanaka H; Uno A; Takenaka Y; Suzuki M; Seo Y; Takemoto N; Fukusumi T; Eguchi H; Kanai H; Horie M; Isohashi F; Ogawa K; Yachida S; Inohara H
    JCO Precis Oncol; 2023 Feb; 7():e2200494. PubMed ID: 36787504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor HPV DNA complements PET-CT in guiding management after radiotherapy in HPV-related squamous cell carcinoma of the head and neck.
    Tanaka H; Takemoto N; Horie M; Takai E; Fukusumi T; Suzuki M; Eguchi H; Komukai S; Tatsumi M; Isohashi F; Ogawa K; Yachida S; Inohara H
    Int J Cancer; 2021 Feb; 148(4):995-1005. PubMed ID: 32895945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer.
    Chera BS; Kumar S; Beaty BT; Marron D; Jefferys S; Green R; Goldman EC; Amdur R; Sheets N; Dagan R; Hayes DN; Weiss J; Grilley-Olson JE; Zanation A; Hackman T; Blumberg JM; Patel S; Weissler M; Tan XM; Parker JS; Mendenhall W; Gupta GP
    Clin Cancer Res; 2019 Aug; 25(15):4682-4690. PubMed ID: 31088830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
    Adrian G; Forslund O; Pedersen L; Sjövall J; Gebre-Medhin M
    Radiother Oncol; 2023 Sep; 186():109773. PubMed ID: 37385383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer and cancer of unknown primary.
    Tanaka H; Suzuki M; Takemoto N; Fukusumi T; Eguchi H; Takai E; Kanai H; Tatsumi M; Horie M; Takenaka Y; Yachida S; Inohara H
    Int J Cancer; 2022 Jan; 150(1):174-186. PubMed ID: 34486724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.
    Rettig EM; Faden DL; Sandhu S; Wong K; Faquin WC; Warinner C; Stephens P; Kumar S; Kuperwasser C; Richmon JD; Uppaluri R; Varvares M; Sethi R; Hanna GJ; Sroussi H
    Int J Cancer; 2022 Oct; 151(7):1081-1085. PubMed ID: 35262203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of circulating tumor HPV16DNA levels and quantitative PET parameters in patients with HPV-positive head and neck squamous cell carcinoma.
    Tatsumi M; Tanaka H; Takenaka Y; Suzuki M; Fukusumi T; Eguchi H; Watabe T; Kato H; Yachida S; Inohara H; Tomiyama N
    Sci Rep; 2024 Feb; 14(1):3278. PubMed ID: 38332246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
    Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
    Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
    Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy dose and survival outcomes in human papillomavirus positive oropharyngeal cancer.
    Tam M; Wu SP; Gerber NK; Lee A; Schreiber D; Givi B; Hu K
    J Laryngol Otol; 2020 Jun; 134(6):533-540. PubMed ID: 32616096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
    Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
    Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.
    Yamamoto Y; Takemoto N; Michiba T; Seo Y; Isohashi F; Otani K; Suzuki M; Fujii T; Yoshii T; Mitani K; Yasui T; Cho H; Tomita Y; Morii E; Teshima T; Ogawa K; Inohara H
    Int J Clin Oncol; 2019 Jun; 24(6):640-648. PubMed ID: 30694402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Mazurek AM; Rutkowski T; Śnietura M; Pigłowski W; Suwiński R; Składowski K
    Head Neck; 2019 Mar; 41(3):632-641. PubMed ID: 30566259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
    Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HPV-Vaccinated Patient With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
    Garset-Zamani M; von Buchwald C; Karevold G; Agander TK; Mateu-Regué À; Eide HA; Tvedskov JF
    JAMA Otolaryngol Head Neck Surg; 2023 Jan; 149(1):92-94. PubMed ID: 36416857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.